ME00354B - Novi lekovi za tretiranje hronićnog opstruktivnog oboljenja pluća - Google Patents
Novi lekovi za tretiranje hronićnog opstruktivnog oboljenja plućaInfo
- Publication number
- ME00354B ME00354B MEP-2008-536A MEP53608A ME00354B ME 00354 B ME00354 B ME 00354B ME P53608 A MEP53608 A ME P53608A ME 00354 B ME00354 B ME 00354B
- Authority
- ME
- Montenegro
- Prior art keywords
- methyl
- hydrogen
- group
- alkyl
- general formula
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000004072 lung Anatomy 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000000414 obstructive effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 34
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 10
- 239000003814 drug Substances 0.000 claims abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 35
- 239000001257 hydrogen Substances 0.000 claims 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 23
- 150000002431 hydrogen Chemical group 0.000 claims 21
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 18
- 229910052731 fluorine Inorganic materials 0.000 claims 18
- 239000011737 fluorine Chemical group 0.000 claims 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 17
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 17
- 229910052801 chlorine Inorganic materials 0.000 claims 17
- 239000000460 chlorine Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical group 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- -1 methoxy, ethoxy Chemical group 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Pronalazak se odnosi na upotrebu jedinjenja opšte formule (I), u kojoj ostaci R 1 , R 2 i R 3 mogu da imaju značenja navedena u patentnim zahtevima i u opisu, za pripremanje leka za tretiranje (lečenje) COPD-a (chronic obstructive pulmonary disease = hronično opstruktivno oboljenje pluća), kao i na nova jedinjenja opšte formule (I) kao takva.
Claims (27)
1.Upotreba jedinjenja, opšte formule 1, u kojoj označavaju n 1 ili 2, R1 vodonik, C1-4-alkil, halogen, OH ili -O-C1-C4-alkil grupu; R2 vodonik, C1-C4-alkil, halogen, OH ili -O-C1-C4-alkil grupu; R1 vodonik, C1-C4-alkil, OH, halogen, -O-C1-C4-alkil, -O-C1-C4-alkilen-COOH ili -O-C1-C4-alkilen-CO-O-C1-C4-alkil grupu, za pripremanje leka za tretiranje COPD-a.
2.Upotreba jedinjenja, prema zahtevu 1, opšte formule 1, u kojoj označavaju n 1 ili 2, R1 vodonik, halogen, ili -C1-C4-alkil grupu; R2 vodonik, halogen, ili -C1-C4-alkil grupu; R1 vodonik, C1-C4-alkil, OH, halogen, -O-C1-C4-alkil, -O-C1-C4-alkilen-COOH ili -O-C1-C4-alkilen-CO-O-C1-C4-alkil grupu, za pripremanje leka za tretiranje COPD-a. za pripremanje leka za tretiranje COPD-a.
3.Upotreba jedinjenja, prema zahtevu 1 ili 2, opšte formule 1, u kojoj označavaju n 1 ili 2, R1 vodonik, fluor, hlor ili metil grupu; R2 vodonik, fluor, hlor ili metil grupu; R1 vodonik, C1-C4-alkil, OH, fluor, hlor, brom, -O-C1-C4-alkil, -O-C1-C4-alkilen-COOH ili -O-C1-C4-alkilen-CO-O-C1-C4-alkil grupu.
4.Upotreba jedinjenja, prema zahtevu 1 ili 2, opšte formule 1, u kojoj označavaju n 1 ili 2, R1 vodonik, metil ili etil grupu; R2 vodonik, metil ili etil grupu; R3 vodonik, metil, etil, OH, metoksi, etoksi, -O-CH2-COOH, -O-CH2-CO-O-metil ili -O-CH2-C00-etil grupu, za pripremanje leka za tretiranje COPD-a.
5.Upotreba jedinjenja, prema nekom od zahteva 1 do 4, opšte formule 1, u kojoj označavaju n 1 ili 2, R1 vodonik ili metil; R2 vodonik ili metil; R3 vodonik, metil, OH, metoksi, -O-CH2-COOH, ili -O-CH2-C00-etil grupu, za pripremanje leka za tretiranje COPD-a.
6. Upotreba jedinjenja, opšte formule 1, prema nekom od zahteva 1 do 5, pri čemu jedinjenja opšte formule 1, jesu u obliku pojedinačnih optičkih izomera, smeša pojedinačnih enantiomera ili racemata, prvenstveno u obliku jedinjenja koja su čisti enantiomeri.
7. Upotreba jedinjenja, opšte formule 1, prema nekom od zahteva 1 do 6, pri čemu jedinjenja opšte formule 1, jesu u obliku adicionih soli sa farmakološki neškodljivim kiselinama, kao i, u datom slučaju, u obliku solvata i/ili hidrata.
8. Jedinjenja opšte formule 1 R1 vodonik, halogen, C1-C4-alkil ili -O-C1-C4-alkil grupu; R2 vodonik, halogen, C1-C4-alkil ili -O-C1-C4-alkil grupu; R3 C1-C4-alkil, OH, halogen, -O-C1-C4-alkil, -O-C1-C4-alkilen-COOH ili -O-C1-C4-alkilen-CO-O-C1-C4-alkil grupu, uz uslov, da kada R1 i R2 pojedinačno označavaju orto-metil grupu, R3 ne može jednovremeno da bude OH.
9. Jedinjenja, prema zahtevu 8, opšte formule 1., u kojoj označavaju n 1; R1 vodonik, fluor, hlor, metil ili metoksi grupu; R2 vodonik, fluor, hlor, metil ili metoksi grupu; R3 C1-C4-alkil, OH, fluor, hlor, brom, -O-C1-C4-alkil, -O-C1-C4-alkilen-COOH ili -O-C1-C4-alkilen-CO-O-C1-C4-alkil grupu, uz uslov, da kada R1 i R2 pojedinačno označavaju orto-metil grupu, R3 ne može jednovremeno da bude OH.
10. Jedinjenja, prema zahtevu 8, opšte formule i, u kojoj označavaju n 1; R1 vodonik ili C1-C4-alkil grupu; R2 vodonik ili C1-C4-alkil grupu; R3 C1-C4-alkil, OH, -O-C1-C4-alkil, -O-C1-C4-alkilen-COOH ili -O-C1-C4-alkilen-CO-O-C1-C4-alkil grupu, uz uslov, da kada R1 i R2 pojedinačno označavaju orto-metil grupu, R3 ne može jednovremeno da bude OH.
11. Jedinjenja, prema zahtevu 8, opšte formule 1, u kojoj označavaju n 1; R1 vodonik, metil ili etil grupu; R2 vodonik, metil ili etil grupu; R3 metil, etil, OH, metoksi, etoksi, -O-CH2-COOH, -O-CH2-C00-metil ili -O-CH2-C00-etil grupu, uz uslov, da kada R1 i R2 pojedinačno označavaju orto-metil grupu, R3 ne može jednovremeno da bude OH.
12. Jedinjenja, prema nekom od zahteva 8 do 11, opšte formule 1, u kojoj označavaju R3 metoksi, etoksi, -O-CH2-COOH, ili -O-CH2-C00-metil ili -O-CH2-C00-etil grupu, a R1, R2 i n, mogu da imaju značenja navedena u zahtevima 8 do 11.
13. Jedinjenja, prema zahtevu 8, opšte formule 1, u kojoj označavaju n 1; R1 halogen, C1-C4-alkil ili -O-C1-C4-alkil grupu; R2 halogen, C1-C4-alkil ili -O-C1-C4-alkil grupu; R3 halogen, C1-C4-alkil ili -O-C1-C4-alkil grupu.
14. Jedinjenja, prema zahtevu 13, opšte formule 1, u kojoj označavaju n 1; R1 fluor, hlor, metil ili metoksi grupu; R2 fluor, hlor, metil ili metoksi grupu; R3 fluor, hlor, metil ili metoksi grupu.
15. Jedinjenja, prema zahtevu 8, opšte formule 1, u kojoj označavaju n 1; R1 vodonik; R2 vodonik, fluor, hlor ili metil grupu; R3 metil, etil, izo-propil, terc. -butil, OH, fluor, hlor, brom, metoksi, etoksi, -O-CH2-COOH, -O-CH2-CH2-COOH, -O-CH2-CH2-CH2-COOH, -O-CH2-COO-metil, -O-CH2-C00-etil, -O-CH2-CH2-C00-metil, -O-CH2-CH2-C00-etil, -O-CH2-CH2-CH2-C00-metil, -O-CH2-CH2-CH2-C00-etil grupu.
16. Jedinjenja, prema zahtevu 15, opšte formule 1, u kojoj označavaju n 1; R1 vodonik; R2 vodonik, fluor, hlor ili metil grupu; R3 OH, fluor, hlor, metil, metoksi, etoksi ili -O-CH2-COOH grupu.
17. Jedinjenja, prema zahtevu 8, opšte formule 1, u kojoj označavaju n 1; R1 i R2 vodonik; R3 metil, etil, izo-propil, terc. -butil, OH, fluor, hlor, brom, metoksi, etoksi, -O-CH2-COOH, -O-CH2-CH2-COOH, -O-CH2-CH2-CH2-COOH, -O-CH2-C00-metil, -O-CH2-C00-etil, -O-CH2-CH2-C00-metil, -O-CH2-CH2-COO-etil, -O-CH2-CH2-CH2-C00-metil, -O-CH2-CH2-CH2-C00-etil grupu.
18. Jedinjenja, prema zahtevu 17, opšte formule 1, u kojoj označavaju n 1; R1 i R2 vodonik; R3 OH, fluor, hlor, metoksi, etoksi, -O-CH2-COOH, prvenstveno OH, fluor, hlor, etoksi ili metoksi grupu.
19. Jedinjenja, prema zahtevu 8, opšte formule 1, u kojoj označavaju n 1; R1 vodonik, halogen, C1-C4-alkil ili -O-C1-C4-alkil grupu; R2 vodonik, halogen, C1-C4-alkil ili -O-C1-C4-alkil grupu; R3 vodonik.
20. Jedinjenja, prema zahtevu 19, opšte formule 1, u kojoj označavaju n 1; R1 vodonik, fluor, hlor, metil ili metoksi grupu; R2 vodonik, fluor, hlor, metil ili metoksi grupu; R3 vodonik.
21. Jedinjenja, opšte formule 1, prema nekom od zahteva 8 do 20, pri čemu jedinjenja opšte formule 1, jesu u obliku pojedinačnih optičkih izomera, smeša pojedinačnih enantiomera ili racemata, prvenstveno u obliku jedinjenja koja su čisti enantiomeri.
22. Jedinjenja, opšte formule 1, prema nekom od zahteva 8 do 21, pri čemu jedinjenja opšte formule 1, jesu u obliku adicionih soli sa farmakološki neškodljivim kiselinama, kao i, u datom slučaju, u obliku solvata i/ili hidrata.
23. Upotreba kao leka, jedinjenja opšte formule 1, prema nekom od zahteva 8 do 22.
24. Upotreba jedinjenja opšte formule 1, prema nekom od zahteva 8 do 22, za pripremanje leka za tretiranje (lečenje) COPD-a (hronično opstruktivno oboljenje pluća).
25. Farmaceutska formulacija, naznačena time, što sadrži neko jedinjenje formule 1, prema nekom od zahteva 8 do 22.
26. Farmaceutska formulacija, koja može da se inhalativno primeni, naznačena time, što sadrži neko jedinjenje formule 1, prema nekom od zahteva 8 do 22.
27. Farmaceutska formulacija, koja može inhalativno da se primeni, prema zahtevu 26, naznačena time, što je odabrana iz grupe koju sačinjavaju inhalacioni prahovi, dozimi aerosolovi, koji sadrže potisni gas i inhalacioni rastvori, koji ne sadrže potisni gas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10253282A DE10253282A1 (de) | 2002-11-15 | 2002-11-15 | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| YU20050361A RS51607B (sr) | 2002-11-15 | 2003-11-11 | Novi lekovi za tretiranje hroničnog opstruktivnog oboljenja pluća |
| PCT/EP2003/012565 WO2004045618A2 (de) | 2002-11-15 | 2003-11-11 | Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MEP53608A MEP53608A (en) | 2011-05-10 |
| ME00354B true ME00354B (me) | 2011-10-10 |
Family
ID=32185709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-536A ME00354B (me) | 2002-11-15 | 2003-11-11 | Novi lekovi za tretiranje hronićnog opstruktivnog oboljenja pluća |
Country Status (38)
| Country | Link |
|---|---|
| EP (2) | EP1562603B3 (me) |
| JP (1) | JP4317138B2 (me) |
| KR (1) | KR101092247B1 (me) |
| CN (3) | CN101817800A (me) |
| AR (2) | AR041969A1 (me) |
| AT (1) | ATE430569T1 (me) |
| AU (1) | AU2003285326B2 (me) |
| BE (1) | BE2014C016I2 (me) |
| BR (1) | BRPI0316264B8 (me) |
| CA (1) | CA2506082C (me) |
| CO (1) | CO5570670A2 (me) |
| CY (2) | CY1110500T1 (me) |
| DE (2) | DE10253282A1 (me) |
| DK (1) | DK1562603T3 (me) |
| EA (1) | EA008665B1 (me) |
| EC (1) | ECSP055774A (me) |
| ES (1) | ES2326878T7 (me) |
| FR (1) | FR14C0049I2 (me) |
| HR (1) | HRP20050432B1 (me) |
| HU (1) | HUS1400011I1 (me) |
| IL (1) | IL167900A (me) |
| LT (1) | LTC1562603I2 (me) |
| LU (1) | LU92433I2 (me) |
| ME (1) | ME00354B (me) |
| MX (1) | MXPA05005081A (me) |
| MY (1) | MY136034A (me) |
| NL (1) | NL300650I2 (me) |
| NO (2) | NO334314B1 (me) |
| NZ (1) | NZ540661A (me) |
| PE (1) | PE20040694A1 (me) |
| PL (1) | PL212238B1 (me) |
| PT (1) | PT1562603E (me) |
| RS (1) | RS51607B (me) |
| SI (1) | SI1562603T1 (me) |
| TW (1) | TWI343812B (me) |
| UA (1) | UA81276C2 (me) |
| WO (1) | WO2004045618A2 (me) |
| ZA (1) | ZA200502246B (me) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| DE102004019539A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von Atemwegserkrankungen |
| DK2422786T3 (da) * | 2004-04-22 | 2014-11-17 | Boehringer Ingelheim Int | Nye lægemiddelkombinationer til behandling af luftvejssygdomme |
| JP2007537187A (ja) * | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物 |
| DE102004024451A1 (de) * | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
| US7745621B2 (en) | 2004-05-14 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Long acting bronchodilators for the treatment of respiratory diseases |
| DE102004024453A1 (de) * | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
| DE102004024454A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004024452A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation von Betaagonisten |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| DE102005007654A1 (de) * | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| DE102005030733A1 (de) * | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
| EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| BRPI0614410A2 (pt) | 2005-08-15 | 2011-03-29 | Boehringer Ingelheim Int | processo para preparação de betamiméticos |
| US20070088030A1 (en) * | 2005-10-10 | 2007-04-19 | Barbara Niklaus-Humke | Aerosol formulations for the inhalation of beta-agonists |
| TWI396541B (zh) | 2005-10-10 | 2013-05-21 | Boehringer Ingelheim Int | 用於治療呼吸疾病之新穎藥物組合 |
| EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| CA2627726A1 (en) * | 2005-11-09 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Aerosolformulation for inhalation |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| JP2009526817A (ja) * | 2006-02-16 | 2009-07-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療用医薬組成物 |
| PE20080142A1 (es) * | 2006-03-15 | 2008-04-14 | Boehringer Ingelheim Int | Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion |
| SI2013211T1 (sl) | 2006-04-21 | 2012-07-31 | Novartis Ag | Purinski derivati za uporabo kot agonisti receptorja adenozina A A |
| WO2008017638A1 (de) * | 2006-08-07 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| UY30543A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
| UY30542A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
| MX2009003185A (es) | 2006-09-29 | 2009-04-03 | Novartis Ag | Pirazolopirimidinas como inhibidores de lipido cinasa pi3k. |
| CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
| PL2104535T3 (pl) | 2007-01-10 | 2011-05-31 | Irm Llc | Związki i kompozycje jako inhibitory proteazy aktywujące kanały |
| AR065017A1 (es) * | 2007-01-25 | 2009-05-13 | Boehringer Ingelheim Int | Procedimiento para la preparacion de betamimeticos |
| AU2008248598B2 (en) | 2007-05-07 | 2011-11-17 | Novartis Ag | Organic compounds |
| PL2444120T3 (pl) | 2007-12-10 | 2018-02-28 | Novartis Ag | Spirocyklicze analogi amiloridu jako blokery ENac |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| JP5555255B2 (ja) | 2008-12-30 | 2014-07-23 | プルマゲン セラピューティクス（インフラメーション）リミテッド | 呼吸器疾患の治療のためのスルホンアミド化合物 |
| PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| KR101721280B1 (ko) | 2009-08-17 | 2017-03-29 | 인텔리카인, 엘엘씨 | 헤테로사이클릭 화합물 및 이의 용도 |
| EP2490687A1 (en) | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| MX390695B (es) * | 2010-09-21 | 2025-03-21 | Intekrin Therapeutics Inc | Composiciones farmaceuticas solidas antidiabeticas |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
| GEP20156285B (en) | 2011-02-25 | 2015-05-11 | Aierem Elelsi | Compounds and compositions as trk inhibitors |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| CN110507654A (zh) | 2012-04-03 | 2019-11-29 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
| EP2906218B1 (en) | 2012-10-09 | 2016-12-14 | Boehringer Ingelheim International GmbH | Beta-2-adrenoceptor agonist for the treatment of cough |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| EA033571B1 (ru) | 2014-04-24 | 2019-11-06 | Novartis Ag | Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| BR112017001695A2 (pt) | 2014-07-31 | 2017-11-21 | Novartis Ag | terapia de combinação |
| US20200069679A1 (en) | 2016-12-12 | 2020-03-05 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol |
| WO2018114887A1 (en) | 2016-12-20 | 2018-06-28 | Laboratorios Lesvi, S.L. | Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride |
| CN108997248B (zh) * | 2018-08-06 | 2023-08-01 | 上海方予健康医药科技有限公司 | 盐酸奥达特罗晶型b及其制备方法 |
| CN109096218B (zh) * | 2018-08-06 | 2020-10-27 | 上海方予健康医药科技有限公司 | 盐酸奥达特罗晶型a及其制备方法 |
| MX2021015133A (es) | 2019-06-10 | 2022-01-24 | Novartis Ag | Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia. |
| PE20220346A1 (es) | 2019-08-28 | 2022-03-14 | Novartis Ag | Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades |
| US11304897B2 (en) | 2020-06-09 | 2022-04-19 | Anovent Pharmaceutical (U.S.), Llc | Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate |
| US11331322B1 (en) | 2021-09-15 | 2022-05-17 | Santen Pharmaceutical Co., Ltd. | Medicament for preventing and/or treating dry eye |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3134590A1 (de) * | 1981-09-01 | 1983-03-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue benzo-heterocyclen |
| US4460581A (en) | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
| EP1305300A1 (de) * | 2000-04-27 | 2003-05-02 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel |
-
2002
- 2002-11-15 DE DE10253282A patent/DE10253282A1/de not_active Withdrawn
-
2003
- 2003-11-11 NZ NZ540661A patent/NZ540661A/en not_active IP Right Cessation
- 2003-11-11 PL PL375270A patent/PL212238B1/pl unknown
- 2003-11-11 EP EP03778312.3A patent/EP1562603B3/de not_active Expired - Lifetime
- 2003-11-11 HR HR20050432A patent/HRP20050432B1/xx not_active IP Right Cessation
- 2003-11-11 SI SI200331634T patent/SI1562603T1/sl unknown
- 2003-11-11 AU AU2003285326A patent/AU2003285326B2/en active Active
- 2003-11-11 UA UAA200505926A patent/UA81276C2/uk unknown
- 2003-11-11 WO PCT/EP2003/012565 patent/WO2004045618A2/de not_active Ceased
- 2003-11-11 JP JP2004552561A patent/JP4317138B2/ja not_active Expired - Lifetime
- 2003-11-11 DE DE50311502T patent/DE50311502D1/de not_active Expired - Lifetime
- 2003-11-11 ME MEP-2008-536A patent/ME00354B/me unknown
- 2003-11-11 MX MXPA05005081A patent/MXPA05005081A/es active IP Right Grant
- 2003-11-11 CN CN201010004697A patent/CN101817800A/zh active Pending
- 2003-11-11 EA EA200500715A patent/EA008665B1/ru active Protection Beyond IP Right Term
- 2003-11-11 PT PT03778312T patent/PT1562603E/pt unknown
- 2003-11-11 AT AT03778312T patent/ATE430569T1/de active
- 2003-11-11 CN CNA2003801030945A patent/CN1713914A/zh active Pending
- 2003-11-11 CA CA2506082A patent/CA2506082C/en not_active Expired - Lifetime
- 2003-11-11 BR BRPI0316264A patent/BRPI0316264B8/pt active IP Right Grant
- 2003-11-11 KR KR1020057008679A patent/KR101092247B1/ko not_active Expired - Lifetime
- 2003-11-11 EP EP08169872A patent/EP2025338A1/de not_active Withdrawn
- 2003-11-11 RS YU20050361A patent/RS51607B/sr unknown
- 2003-11-11 DK DK03778312T patent/DK1562603T3/da active
- 2003-11-11 ES ES03778312.3T patent/ES2326878T7/es active Active
- 2003-11-11 CN CN200910266327A patent/CN101735166A/zh active Pending
- 2003-11-13 PE PE2003001147A patent/PE20040694A1/es active IP Right Grant
- 2003-11-13 MY MYPI20034360A patent/MY136034A/en unknown
- 2003-11-14 TW TW092132031A patent/TWI343812B/zh active
- 2003-11-14 AR ARP030104201A patent/AR041969A1/es not_active Application Discontinuation
-
2005
- 2005-03-17 ZA ZA2005/02246A patent/ZA200502246B/en unknown
- 2005-04-07 IL IL167900A patent/IL167900A/en active Protection Beyond IP Right Term
- 2005-05-02 EC EC2005005774A patent/ECSP055774A/es unknown
- 2005-06-14 CO CO05057641A patent/CO5570670A2/es not_active Application Discontinuation
- 2005-06-14 NO NO20052883A patent/NO334314B1/no not_active IP Right Cessation
-
2009
- 2009-08-04 CY CY20091100826T patent/CY1110500T1/el unknown
-
2012
- 2012-07-19 AR ARP120102613A patent/AR087241A2/es unknown
-
2014
- 2014-02-27 BE BE2014C016C patent/BE2014C016I2/fr unknown
- 2014-03-06 LT LTPA2014012C patent/LTC1562603I2/lt unknown
- 2014-03-07 NL NL300650C patent/NL300650I2/nl unknown
- 2014-03-07 HU HUS1400011C patent/HUS1400011I1/hu unknown
- 2014-03-10 NO NO2014005C patent/NO2014005I1/no unknown
- 2014-04-22 LU LU92433C patent/LU92433I2/fr unknown
- 2014-06-23 FR FR14C0049C patent/FR14C0049I2/fr active Active
- 2014-08-13 CY CY2014032C patent/CY2014032I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00354B (me) | Novi lekovi za tretiranje hronićnog opstruktivnog oboljenja pluća | |
| WO2004037807A3 (en) | Medicinal arylethanolamine compounds | |
| RU2010108640A (ru) | Новая комбинация терапевтических агентов | |
| EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| AU2003222841A1 (en) | Phenethanolamine derivatives | |
| BG102689A (bg) | Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения | |
| HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
| MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
| MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
| ATE330589T1 (de) | Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege | |
| RU2472783C2 (ru) | Аминные производные и их применение в бета-2-адренорецептор-опосредованных заболеваниях | |
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
| MX2023010087A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| MX2007004740A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica. | |
| SE0102055D0 (sv) | New Compounds | |
| MY145166A (en) | Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof | |
| MX2023010083A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| JPS58914A (ja) | 抗ウイルス作用を有する医薬組成物 | |
| RU2662161C1 (ru) | Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита | |
| CR20230331A (es) | Derivados de pirazolamida | |
| TH67821A (th) | สารรักษาโรคชนิดใหม่เพื่อการรักษาโรคปอดที่เกิดภาวะอุดตันเรื้อรัง | |
| TH66454B (th) | สารรักษาโรคชนิดใหม่เพื่อการรักษาโรคปอดที่เกิดภาวะอุดตันเรื้อรัง | |
| PL371520A1 (en) | New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds | |
| JP2005068089A (ja) | コロナウイルス消毒剤 |